In trans-splicing AAV vector-mediated gene therapy, the accumulation of mRNA, rather than dual vector coinfection efficiency, is a rate-limiting factor.
No takes yet. Share an insight, caveat, or question.
mRNA stability, not coinfection, limits trans-splicing AAV efficacy in muscle; hypothesis-generating for vector optimization pending larger studies.
Xu et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: